Myasthenia gravis in Spain: A survey of specialized neurologists to uncover unmet needs

dc.contributor.authorCortés Vicente, Elena
dc.contributor.authorCasasnovas Pons, Carlos
dc.contributor.authorJuntas, Raúl
dc.contributor.authorSevilla, Teresa
dc.contributor.authorPardo Fernández, Julio
dc.contributor.authorRodríguez de Rivera, F. J.
dc.contributor.authorGuerrero Sola, Antonio
dc.date.accessioned2026-07-03T11:07:49Z
dc.date.available2026-07-03T11:07:49Z
dc.date.issued2025-10-10
dc.date.updated2026-05-22T13:36:04Z
dc.description.abstractIntroduction: Myasthenia gravis (MG) is a neuromuscular autoimmune disease that requires prompt diagnosis and management by neurologists. The challenges of MG management are associated with the diagnostic process and the selection of an effective form of therapy enabling long-term remission of the disease. The objective of this study was to assess the state of MG in Spain to identify unaddressed needs in the clinical progression, diagnosis, and treatment approaches. Methods: A survey was distributed via email between 19 July and 25 October 2022 to neurologists belonging to the Spanish Society of Neurology. A comprehensive descriptive analysis was conducted on all collected data. Results: In total, 69 completed surveys, representing 64 Spanish hospitals, were analyzed and included in the results. The study identified that economic difficulties, such as departmental budgets, have led to a lack of access to antibody testing during diagnosis. Furthermore, corti-costeroids were found to achieve the best clinical response, despite also being associated with a higher frequency of adverse effects. The results show that 34% of patients with MG present active symptoms. Eighteen percent have symptoms that limit their daily activities. Additionally, 29% of patients have requested an unscheduled follow-up visit within the last year. Conclusions: Several areas present unmet needs in terms of improving access to diagnostic assays, residual disease burden in treated patients, and the management and diagnosis of MG. (c) 2025 Sociedad Espanola de Neurolog & imath;a. Published by Elsevier Espana, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/ 4.0/).
dc.format.extent10 p.
dc.format.mimetypeapplication/pdf
dc.identifier.issn1578-1968
dc.identifier.pmid41962987
dc.identifier.urihttps://hdl.handle.net/2445/230414
dc.language.isoeng
dc.publisherElsevier España
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1016/j.nrl.2025.501912
dc.relation.ispartofNeurología, 2025, vol. 41, num. 3
dc.relation.urihttps://doi.org/10.1016/j.nrl.2025.501912
dc.rightscc by-nc-nd (c) Cortés Vicente, Elena et al., 2026
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceArticles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
dc.subject.classificationGestió hospitalària
dc.subject.classificationUrgències en neurologia
dc.subject.otherHospital administration
dc.subject.otherNeurological emergencies
dc.titleMyasthenia gravis in Spain: A survey of specialized neurologists to uncover unmet needs
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
1-s2.0-S0213485325000684-main.pdf
Mida:
557.84 KB
Format:
Adobe Portable Document Format